Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | Marizomib |
| Trade Name | |
| Synonyms | NPI-0052|ML 858|Salinosporamide A|Salinosporin A |
| Drug Descriptions |
Marizomib (NPI-0052) is an irreversible inhibitor of the 20S proteasome, which leads to cell cycle arrest and apoptosis in tumor cells (PMID: 16891470, PMID: 29076150). |
| DrugClasses | |
| CAS Registry Number | 437742-34-2 |
| NCIT ID | C64634 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Bevacizumab + Marizomib | Bevacizumab Marizomib | 0 | 1 |
| Dexamethasone + Marizomib + Pomalidomide | Dexamethasone Marizomib Pomalidomide | 0 | 0 |
| Marizomib | Marizomib | 0 | 2 |
| Marizomib + Panobinostat | Marizomib Panobinostat | 0 | 1 |
| Marizomib + Tinostamustine | Marizomib Tinostamustine | 0 | 0 |
| Marizomib + Vorinostat | Marizomib Vorinostat | 0 | 0 |